Skip to main content
Fig. 3 | Lipids in Health and Disease

Fig. 3

From: Estimating the effect of inclisiran on hypercholesterolemia and primary prevention of cardiovascular disease: the NHANES 1999–2018 study

Fig. 3

Changes in 10-year CVD risk for ASCVD-risk equivalent populations before and after treatment, based on placebo-adjusted effects of inclisiran from the ORION-11 trial. (A) 10-year CVD risk. (B) 10-year CHD risk. (C) 10-year stroke risk. (D) 10-year CHF risk. Abbreviations CVD, cardiovascular disease; CHD, coronary heart disease; CHF, congestive heart failure

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X